Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease

Molecular Genetics and Metabolism

Volumn 107, Issue 3, 2012, Pages 469-479

  Nilsson, Mats I ^a   Samjoo, Imtiaz A ^a   Hettinga, Bart P ^a   Koeberl, Dwight D ^b   Zhang, Haoyue ^b   Hawke, Thomas J ^a   Nissar, Aliyah A ^a   Ali, Tahir ^a   Brandt, Linda ^a   Ansari, Mohammad U ^a   Hazari, Hassan ^a   Patel, Neha ^a   Amon, Jaihoon ^a   Tarnopolsky, Mark A ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acid glucosidase; Autophagy; Exercise; Glycogen; Lysosome; Muscle

Indexed keywords

GLYCOGEN; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE;

AEROBIC EXERCISE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ENDURANCE TRAINING; ENZYME REPLACEMENT; GLYCOGEN STORAGE DISEASE TYPE 2; GRIP STRENGTH; LEAN BODY WEIGHT; MACROAUTOPHAGY; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE; SURGICAL TECHNIQUE; TREADMILL EXERCISE;

ALPHA-GLUCOSIDASES; ANIMALS; ENZYME REPLACEMENT THERAPY; EXERCISE; EXERCISE THERAPY; FEMALE; GLYCOGEN; GLYCOGEN STORAGE DISEASE TYPE II; HEART; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICE; MICE, TRANSGENIC; MUSCLE, SKELETAL; PHYSICAL CONDITIONING, ANIMAL;

ANIMALIA; MUS;

EID: 84867898819     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2012.09.010     Document Type: Article

References (62)

1. Fukuda T., Ahearn M., Roberts A., Mattaliano R.J., Zaal K., Ralston E., Plotz P.H., Raben N. Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease. Mol. Ther. 2006, 14:831-839.
2. Raben N., Takikita S., Pittis M., Bembi B., Suely K.M., Roberts A., Page L., Kishnani P.S., Schoser B., Chien Y.-H., Ralston E., Nagaraju K., Plotz P. Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand. .. Autophagy 2007, 3:546-552.
3. Thurberg B.L., Lynch Maloney C., Vaccaro C., Afonso K., Tsai A.C.-H., Bossen E., Kishnani P.S., O'Callaghan M. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab. Invest. 2006, 86:1208-1220.
4. Geel T.M., McLaughlin P.M.J., de Leij L.F.M.H., Ruiters M.H.J., Niezen-Koning K.E. Pompe disease: current state of treatment modalities and animal models. Mol. Genet. Metab. 2007, 92:299-307.
5. Kishnani P. Recombinant human acid-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007, 68:99-109.
6. Raben N., Danon M., Gilbert A.L., Dwivedi S., Collins B., Thurberg B.L., Mattaliano R.J., Nagaraju K., Plotz P.H. Enzyme replacement therapy in the mouse model of Pompe disease. Mol. Genet. Metab. 2003, 159-169.
7. Drost M.R., Schaart G., van Dijk P., van Capelle C.I., van Der Vusse G.J., Delhaas T., van Der Ploeg A.T., Reuser A.J.J. Both type 1 and type 2a muscle fibers can respond to enzyme therapy in Pompe disease. Muscle Nerve 2008, 37:251-255.
8. Koeberl D.D., Luo X., Sun B., McVie-Wylie A., Dai J., Li S., Banugaria S.G., Chen Y.T., Bali D.S. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle. Mol. Genet. Metab. 2011, 103:107-112.
9. Raben N., Fukuda T., Gilbert A., Dejong D., Thurberg B., Mattaliano R., Meikle P., Hopwood J., Nagashima K., Nagaraju K. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Mol. Ther. 2005, 11:48-56.
10. Raben N., Hill V., Shea L., Takikita S., Baum R., Mizushima N., Ralston E., Plotz P. Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease. Hum. Mol. Genet. 2008, 17:3897-3908.
11. Laughlin M.H., Roseguini B. Mechanisms for exercise training-induced increases in skeletal muscle blood flow capacity: differences with interval sprint training versus aerobic endurance training. J. Physiol. Pharmacol. 2008, 59(Suppl. 7):71-88.
12. Fukuda T., Ewan L., Bauer M., Mattaliano R.J., Zaal K., Ralston E., Plotz P.H., Raben N. Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease. Ann. Neurol. 2006, 59:700-708.
13. Hawes M.L., Kennedy W., O'Callaghan M.W., Thurberg B.L. Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe disease. Mol. Genet. Metab. 2007, 91:343-351.
14. Amalfitano A., McVie-Wylie A.J., Hu H., Dawson T.L., Raben N., Plotz P., Chen Y.T. Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Proc. Natl. Acad. Sci. 1999, 96:8861-8866.
15. Sun B., Zhang H., Bird A., Li S., Young S.P., Koeberl D.D. Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high-level vector-mediated transgene expression. J. Gene Med. 2009, 11:913-920.
16. Zhang P., Sun B., Osada T., Rodriguiz R., Yang X.Y., Luo X., Kemper A.R., Clay T.M., Koeberl D.D. Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine Pompe disease. Hum. Gene Ther. 2012, 23(5):460-472.
17. Yoshimizu M., Tajima Y., Matsuzawa F., Aikawa S.-i., Iwamoto K., Kobayashi T., Edmunds T., Fujishima K., Tsuji D., Itoh K., Ikekita M., Kawashima I., Sugawara K., Ohyanagi N., Suzuki T., Togawa T., Ohno K., Sakuraba H. Binding parameters and thermodynamics of the interaction of imino sugars with a recombinant human acid alpha-glucosidase (alglucosidase alfa): insight into the complex formation mechanism. Clin. Chim. Acta 2008, 391:68-73.
18. Douillard-Guilloux G., Raben N., Takikita S., Ferry A., Vignaud A., Guillet-Deniau I., Favier M., Thurberg B.L., Roach P.J., Caillaud C., Richard E. Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of Pompe disease. Hum. Mol. Genet. 2009, 19:684-696.
19. Orchard P.J., Blazar B.R., Wagner J., Charnas L., Krivit W., Tolar J. Hematopoietic cell therapy for metabolic disease. J. Pediatr. 2007, 151:340-346.
20. Matalon R., Surendran S., Campbell G.A., Michals-Matalon K., Tyring S.K., Grady J., Cheng S., Kaye E. Hyaluronidase increases the biodistribution of acid alpha-1,4 glucosidase in the muscle of Pompe disease mice: an approach to enhance the efficacy of enzyme replacement therapy. Biochem. Biophys. Res. Commun. 2006, 350:783-787.
21. Zhu Y., Li X., McVie-Wylie A., Jiang C., Thurberg B.L., Raben N., Mattaliano R.J., Cheng S.H. Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice. Biochem. J. 2005, 389:619-628.
22. 2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease. Mol. Genet. Metab. 2012, 105:221-227.
23. Case L., Kishnani P. Physical therapy management of Pompe disease. Genet. Med. 2006, 8:318-327.
24. Case L.E., Beckemeyer A.A., Kishnani P.S. Infantile Pompe disease on ERT-update on clinical presentation, musculoskeletal management, and exercise considerations. Am. J. Med. Genet. C Semin. Med. Genet. 2012, 160C:69-79.
25. Jones H.N., Moss T., Edwards L., Kishnani P.S. Increased inspiratory and expiratory muscle strength following respiratory muscle strength training (RMST) in two patients with late-onset Pompe disease. Mol. Genet. Metab. 2011, 104:417-420.
26. Khan A., Ramage B., Robu I., Benard L. Side-alternating vibration training improves muscle performance in a patient with late-onset Pompe disease. Case Rep. Med. 2009, 741087:1-4.
27. Slonim A.E., Bulone L., Goldberg T., Minikes J., Slonim E., Galanko J., Martiniuk F. Modification of the natural history of adult-onset acid maltase deficiency by nutrition and exercise therapy. Muscle Nerve 2007, 35:70-77.
28. Strothotte S., Strigl-Pill N., Grunert B., Kornblum C., Eger K., Wessig C., Deschauer M., Breunig F., Glocker F.X., Vielhaber S., et al. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J. Neurol. 2010, 257:91-97.
29. Terzis G., Dimopoulos F., Papadimas G.K., Papadopoulos C., Spengos K., Fatouros I., Kavouras S.A., Manta P. Effect of aerobic and resistance exercise training on late-onset Pompe disease patients receiving enzyme replacement therapy. Mol. Genet. Metab. 2011, 104:279-283.
30. Safdar A., Bourgeois J.M., Ogborn D.I., Little J.P., Hettinga B.P., Akhtar M., Thompson J.E., Melov S., Mocellin N.J., Kujoth G.C., Prolla T.A., Tarnopolsky M.A. Endurance exercise rescues progeroid aging and induces systemic mitochondrial rejuvenation in mtDNA mutator mice. Proc. Natl. Acad. Sci. 2011, 108:4135-4140.
31. Goodyear L.J. The exercise pill: too good to be true?. N. Engl. J. Med. 2008, 359:1842-1844.
32. Bassett D., Howley E. Limiting factors for maximum oxygen uptake and determinants of endurance performance. Med. Sci. Sports Exercise 2000, 32:70.
33. Grumati P., Coletto L., Schiavinato A., Castagnaro S., Bertaggia E., Sandri M., Bonaldo P. Physical exercise stimulates autophagy in normal skeletal muscles but is detrimental for collagen VI-deficient muscles. Autophagy 2011, 7:1415-1423.
34. He C., Bassik M.C., Moresi V., Sun K., Wei Y., Zou Z., An Z., Loh J., Fisher J., Sun Q., Korsmeyer S., Packer M., May H.I., Hill J.A., Virgin H.W., Gilpin C., Xiao G., Bassel-Duby R., Scherer P.E., Levine B. Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. Nature 2012, 481:511-515.
35. Klionsky Daniel J., Saltiel Alan R. Autophagy works out. Cell Metab. 2012, 15:273-274.
36. Hood D.A. Mechanisms of exercise-induced mitochondrial biogenesis in skeletal muscle. Appl. Physiol. Nutr. Metab. 2009, 34. (Report), 465(468).
37. Raben N., Nagaraju K., Lee E., Kessler P., Byrne B., Lee L., LaMarca M., King C., Ward J., Sauer B., Plotz P. Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J. Biol. Chem. 1998, 273:19086-19092.
38. PMDA Review Report: Myozyme (Alglucosidase Alfa [Genetical Recombination]), Japan 2007.
39. Reuser A.J., Koster J.F., Hoogeveen A., Galjaard H. Biochemical, immunological, and cell genetic studies in glycogenosis type II. Am. J. Hum. Genet. 1978, 30:132-143.
40. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 1985, 150:76-85.
41. A. Safdar, M.J. Hamadeh, J.J. Kaczor, S. Raha, J. deBeer, M.A. Tarnopolsky, Aberrant mitochondrial homeostasis in the skeletal muscle of sedentary older adults, PLoS One 5 (2010) e10778.
42. Carter S., Rennie C., Hamilton S., Tarnopolsky M.A. Changes in skeletal muscle in males and females following endurance training. Can. J. Physiol. Pharmacol. 2005, 79:386-392.
43. Abadi A., Glover E.I., Isfort R.J., Raha S., Safdar A., Yasuda N., Kaczor J.J., Melov S., Hubbard A., Qu X., Phillips S.M., Tarnopolsky M. Limb immobilization induces a coordinate down-regulation of mitochondrial and other metabolic pathways in men and women. PLoS One 2009, 4:e6518.
44. Payne E.T., Yasuda N., Bourgeois J.M., Devries M.C., Rodriguez M.C., Yousuf J., Tarnopolsky M.A. Nutritional therapy improves function and complements corticosteroid intervention in mdx mice. Muscle Nerve 2006, 33:66-77.
45. Hamadeh M.J., Rodriguez M.C., Kaczor J.J., Tarnopolsky M.A. Caloric restriction transiently improves motor performance but hastens clinical onset of disease in the Cu/Zn-superoxide dismutase mutant G93A mouse. Muscle Nerve 2005, 31:214-220.
46. Lynch C.M., Johnson J., Vaccaro C., Thurberg B.L. High-resolution light microscopy (HRLM) and digital analysis of Pompe disease pathology. J. Histochem. Cytochem. 2005, 53:63-73.
47. Devries M.C., Hamadeh M.J., Graham T.E., Tarnopolsky M.A. 17{beta}-Estradiol supplementation decreases glucose rate of appearance and disappearance with no effect on glycogen utilization during moderate intensity exercise in men. J. Clin. Endocrinol. Metab. 2005, 90:6218-6225.
48. Adamo K.B., Graham T.E. Comparison of traditional measurements with macroglycogen and proglycogen analysis of muscle glycogen. J. Appl. Physiol. 1998, 84:908-913.
49. Passonneau J., Lowry O. Enzymatic Analysis: A Practical Guide 1993, Humana Press, Totawa, NJ.
50. Otter T., King S.M., Witman G.B. A two-step procedure for efficient electrotransfer of both high-molecular-weight (greater than 400,000) and low-molecular-weight (less than 20,000) proteins. Anal. Biochem. 1987, 162:370-377.
51. Abramoff M.D. Image processing with image. J. Biophotonics Intern. 2004, 11:36-42.
52. Caru B., Colombo E., Santoro F., Laporta A., Maslowsky F. Regional flow responses to exercise. Chest 1992, 101:223S-225S.
53. Khazaeinia T., Ramsey A.A. The effects of exercise on the pharmacokinetics of drugs. J. Pharm. Sci. 2000, 3(3):292-302.
54. Flanagan J.J., Rossi B., Tang K., Wu X., Mascioli K., Donaudy F., Tuzzi M.R., Fontana F., Cubellis M.V., Porto C., Benjamin E., Lockhart D.J., Valenzano K.J., Andria G., Parenti G., Do H.V. The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase. Hum. Mutat. 2009, 30:1683-1692.
55. Martina V., Masha A., Gigliardi V.R., Brocato L., Manzato E., Berchio A., Massarenti P., Settanni F., Della Casa L., Bergamini S.I.A. Long-term N-acetylcysteine and l-arginine administration reduces endothelial activation and systolic blood pressure in hypertensive patients with type 2 diabetes. Diabetes Care 2008, 31(5):940-944.
56. Reid M.B., Stokic D.S., Koch S.M., Khawli F.A., Leis A.A. N-acetylcysteine inhibits muscle fatigue in humans. J. Clin. Invest. 1994, 94:2468-2474.
57. Raben N., Wong A., Ralston E., Myerowitz R. Autophagy and mitochondria in Pompe disease: nothing is so new as what has long been forgotten. Am. J. Med. Genet. C Semin. Med. Genet. 2012, 160C:13-21.
58. Takikita S., Schreiner C., Baum R., Xie T., Ralston E., Plotz P.H., Raben N. Fiber type conversion by PGC-1α activates lysosomal and autophagosomal biogenesis in both unaffected and Pompe skeletal muscle. PLoS One 2010, 5.
59. James A.P., Barnes P.D., Palmer T.N., Fournier P.A. Proglycogen and macroglycogen: artifacts of glycogen extraction?. Metabolism 2008, 57:535-543.
60. Raben N., Schreiner C., Baum R., Takikita S., Xu S., Xie T., Myerowitz R., Komatsu M., Van Der Meulen J.H., Nagaraju K., Ralston E., Plotz P.H. Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder of murine Pompe disease. Autophagy 2010, 6:1078-1089.
61. Raben N., Baum R., Schreiner C., Takikita S., Mizushima N., Ralston E., Plotz P.H. When more is less: excess and deficiency of autophagy coexist in skeletal muscle in Pompe disease. Autophagy 2009, 5:111-113.
62. Mizushima N., Yoshimori T. How to interpret LC3 immunoblotting. Autophagy 2007, 3:542-545.